Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 6/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15147291 | 0.82 | ALDH1A1 (0.38) | PDE2AALDH1A1ENPP1EGLN2 | |
| SCHEMBL13201570 | 0.81 | PDE2A (0.41) | PDE2AALDH1A1RETKDRACVRL1 | |
| SCHEMBL14654141 | 0.79 | ADORA2A (0.39) | ALDH1A1ACVRL1MBOAT4FGFR1FGFR3 | |
| SCHEMBL10260070 | 0.79 | RET (0.40) | PDE2AALDH1A1RETKDRACVRL1 | |
| SCHEMBL14647486 | 0.79 | PDE2A (0.39) | PDE2AACVRL1ADORA2A | |
| SCHEMBL13077692 | 0.79 | RET (0.40) | PDE2ARETKDRACVRL1ADORA2A | |
| SCHEMBL19375829 | 0.77 | ALDH1A1 (0.35) | PDE2AALDH1A1ENPP1EGLN2 | |
| SCHEMBL17114650 | 0.74 | MEN1 (0.35) | PDE2AALDH1A1 | |
| SCHEMBL13618206 | 0.74 | TNK2 (0.55) | — | |
| SCHEMBL279415 | 0.71 | FGFR1 (0.39) | PDE2AALDH1A1RETKDRACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-3858833-A1 | AMINONORDECANE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020063012-A1 | AMINONORDECANE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京亘泰医药技术有限公司 | 2020-04-02 | — | — | WO | disclosed |
| EP-3311818-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | Pharmacyclics, LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-12-21 | — | — | US | disclosed |
| US-9795605-B2 | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors | PHARMACYCLICS LLC (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2307025-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | PHARMACYCLICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9556182-B2 | Inhibitors of Bruton's tyrosine kinase | Pharmacylics LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9278100-B2 | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | PHARMACYCLICS LLC (US) | 2016-03-08 | — | — | US | disclosed |
| US-20120277225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120202264-A1 | INHIBITORS OF IL2-INDUCIBLE T-CELL KINASE | PHARMACYCLICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| WO-2010009342-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYCLICS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2008121742-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362246-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | PDE2A 2287/4885ALDH1A1 4117/4885RET 333/4885 |
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | PDE2A 1173/4885ALDH1A1 3975/4885RET 197/4885 |
| US-20120277225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | PDE2A 2287/4885ALDH1A1 4117/4885RET 333/4885 |
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | PDE2A 2287/4885ALDH1A1 4117/4885RET 333/4885 |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | PDE2A 2287/4885ALDH1A1 4117/4885RET 333/4885 |
| US-20110224235-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | PDE2A 2302/4885ALDH1A1 4521/4885RET 166/4885 |
| US-20120065201-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | PDE2A 2287/4885ALDH1A1 4117/4885RET 333/4885 |
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | BTK, ABL1, LYN | PDE2A 2302/4885ALDH1A1 4521/4885RET 166/4885 |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | PDE2A 1448/4885ALDH1A1 4453/4885RET 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.